Literature DB >> 28147306

Rapid determination of 30 bioactive constituents in XueBiJing injection using ultra high performance liquid chromatography-high resolution hybrid quadrupole-orbitrap mass spectrometry coupled with principal component analysis.

Lihua Zuo1, Zhi Sun2, Yurong Hu3, Ya Sun1, Wenhua Xue1, Lin Zhou1, Jun Zhang1, Xiaoyue Bao1, Zhenfeng Zhu1, Guanglu Suo4, Xiaojian Zhang5.   

Abstract

Xuebijing injection (XBJ) is a traditional Chinese herbal prescription widely used in the treatment of sepsis. Extensive chemical studies revealed that XBJ injection contains amino acids, phenolic acids, flavonoid glycosides, terpeneglycosides and phthalides. In this study, the applicability of ultra high performance liquid chromatography coupled with high resolution hybrid quadruple-orbitrap mass spectrometry (UHPLC-Q-Orbitrap MS) for the simultaneous quantitative analysis of 30 bioactive constituents in XueBiJing injection (XBJ) was investigated. The mass spectrometer was operated in full MS scan mode. The use of 70,000FWHM mass resolution and narrow mass windows (5ppm) could effectively improve the selectivity of the method. Separation was achieved on a Waters ACQUITY UPLC® HSS C18 column (2.1mm×100mm, 1.8μm) with a gradient mobile phase consisting of acetonitrile-water (containing 10mM ammonium acetate) at a flow rate of 0.2mL/min. Satisfactory linearity was achieved within wide linear range and all correlation coefficients (r) of analytes were more than 0.9996. The limits of detection (LODs) were in the range of 0.1180-27.82ng/mL for different analytes. The relative standard deviations (RSDs) of inter- and intra-day precisions were less than 3.0% and the recoveries of the assay were in the range of 98.5%-101.5%. The validated method was successfully applied for simultaneous determination of 30 bioactive compounds in XueBiJing injection from 10 batches samples by UHPLC-Q-Orbitrap MS within 10min. Moreover, the results were evaluated principal component analysis and two compounds might be the most important chemical markers for chemical quality control of XBJ injection. The novel Q-Orbitrap mass spectrometry has been proved to be a very promising and powerful tool for routine screening of bioactive compounds in traditional Chinese medicine injection, ensuring drug safety and public health.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bioactive constituents; Quantitative analysis; UHPLC-Q-Orbitrap MS; XueBiJing injection

Mesh:

Substances:

Year:  2017        PMID: 28147306     DOI: 10.1016/j.jpba.2017.01.024

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  16 in total

1.  COVID-19 managed with early non-invasive ventilation and a bundle pharmacotherapy: A case report.

Authors:  Mian Peng; Di Ren; Xue-Yan Liu; Jin-Xiu Li; Rong-Lin Chen; Bao-Jun Yu; Yong-Feng Liu; Xi Meng; Yan-Si Lyu
Journal:  World J Clin Cases       Date:  2020-05-06       Impact factor: 1.337

2.  Efficacy and safety of Xuebijing injection for radiation pneumonitis: A meta-analysis.

Authors:  Zheng Li; Dandan Wang; Ying Zhang; Shuo Wang; Xueqian Wang; Yuxiao Li; Yuerong Gui; Jun Dong; Wei Hou
Journal:  PLoS One       Date:  2022-06-01       Impact factor: 3.752

3.  A real-world study on adverse drug reactions to Xuebijing injection: hospital intensive monitoring based on 93 hospitals (31,913 cases).

Authors:  Rui Zheng; Hui Wang; Zhi Liu; Xiaohui Wang; Jing Li; Xiang Lei; Yilin Fan; Si Liu; Zhiqiao Feng; Hongcai Shang
Journal:  Ann Transl Med       Date:  2019-03

4.  Antiseptic Activity of Ethnomedicinal Xuebijing Revealed by the Metabolomics Analysis Using UHPLC-Q-Orbitrap HRMS.

Authors:  Lihua Zuo; Lin Zhou; Tanye Xu; Zhuolun Li; Liwei Liu; Yingying Shi; Jian Kang; Guanmin Gao; Shuzhang Du; Zhi Sun; Xiaojian Zhang
Journal:  Front Pharmacol       Date:  2018-03-29       Impact factor: 5.810

5.  XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial.

Authors:  Yuanlin Song; Chen Yao; Yongming Yao; Hui Han; Xiaodong Zhao; Kaijiang Yu; Luyi Liu; Ying Xu; Zhongmin Liu; Qingshan Zhou; Ying Wang; Zhuang Ma; Youguang Zheng; Dawei Wu; Zhongzhi Tang; Minzhou Zhang; Shuming Pan; Yanfen Chai; Yan Song; Jian Zhang; Lei Pan; Yi Liu; He Yu; Xuezhong Yu; Hong Zhang; Xiaoge Wang; Zhaohui Du; Xianyao Wan; Yijun Tang; Yingping Tian; Yimin Zhu; Hongliang Wang; Xiaoyan Yan; Zhi Liu; Boli Zhang; Nanshan Zhong; Hongcai Shang; Chunxue Bai
Journal:  Crit Care Med       Date:  2019-09       Impact factor: 7.598

6.  Systematic Profiling of the Multicomponents and Authentication of Erzhi Pill by UHPLC/Q-Orbitrap-MS Oriented Rapid Polarity-Switching Data-Dependent Acquisition and Selective Monitoring of the Chemical Markers Deduced from Fingerprint Analysis.

Authors:  Li Jia; Lingling Fu; Xiaoyan Wang; Wenzhi Yang; Hongda Wang; Tiantian Zuo; Chunxia Zhang; Ying Hu; Xiumei Gao; Lifeng Han
Journal:  Molecules       Date:  2018-11-30       Impact factor: 4.411

7.  Analysis of the Efficacy and Mechanism of Action of Xuebijing Injection on ARDS Using Meta-Analysis and Network Pharmacology.

Authors:  Yun Zhang; Jie Wang; Yong-Mei Liu; Hui Yang; Guang-Jun Wu; Xuan-Hui He
Journal:  Biomed Res Int       Date:  2021-05-22       Impact factor: 3.411

8.  Rapid Screening and Quantitative Determination of Active Components in Qing-Hua-Yu-Re-Formula Using UHPLC-Q-TOF/MS and HPLC-UV.

Authors:  Xin Shao; Jie Zhao; Xu Wang; Yi Tao
Journal:  J Anal Methods Chem       Date:  2018-03-11       Impact factor: 2.193

9.  Efficacy and Safety of Xuebijing Injection Combined With Ulinastatin as Adjunctive Therapy on Sepsis: A Systematic Review and Meta-Analysis.

Authors:  Guochao Chen; Yanyan Gao; Yue Jiang; Fei Yang; Shuangshuang Li; Di Tan; Qun Ma
Journal:  Front Pharmacol       Date:  2018-07-24       Impact factor: 5.810

10.  UHPLC-Q-TOF MS-Based Metabolic Analysis for the Therapeutic Efficacy of "Xuebijing Injection" against Sepsis-Induced Acute Lung Injury.

Authors:  Xuan Shi; Guannan Chen; Juan Wei; Di Feng; Yuanli Chen; Huanping Zhou; Meiyun Liu; Xin Lv
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-23       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.